Molecular tissue engineering: Concepts, status and challenge

Abstract

Tissue engineering has confronted many difficulties mainly as follows: 1) How to modulate the adherence, proliferation, and oriented differentiation of seed cells, especially that of stemcells. 2) Massive preparation and sustained controllable delivery of tissue inducing factors or plasmid DNA, such as growth factors, angiogenesis stimulators, and so on. 3) Development of “intelligent biomimetic materials” as extracellular matrix with a good superficial and structural compatibility as well as biological activity to stimulate predictable, controllable and desirable responses under defined conditions. Molecular biology is currently one of the most exciting fields of research across life sciences, and the advances in it also bring a bright future for tissue engineering to overcome these difficulties. In recent years, tissue engineering benefits a lot from molecular biology. Only a comprehensive understanding of the involved ingredients of tissue engineering (cells tissue inducing factors, genes, biomaterials) and the subtle relationships between them at molecular level can lead to a successful manipulation of reparative processes and a better biological substitute. Molecular tissue engineering, the offspring of the tissue engineering and molecular biology, has gained an increasing importance in recent years. It offers the promise of not simply replacing tissue, but improving the restoration. The studies presented in this article put forward this new concept for the first time and provide an insight into the basic principles, status and challenges of this emerging technology.

Keywords

tissue engineering / stem cell / gene therapy / biomimetic biomaterials / molecular biology / molecular tissue engineering / growth factor delivery

References

[1] Langer R, Vacanti J. Tissue Engineering. Science, 1993, 260: 920-926.

[2] Ferber D. Tissue Engineering: Lab-grown Organs Begin to Take Shape. Science, 1999, 284(5413): 422-425.

[3] Nasseri B, Ogawa K, Vacanti J. Tissue Engineering: An Evolving 21st-century Science to Provide Biologic Replacement for Reconstruction and Transplantation. Surgery, 2000, 130(5): 781-784.

[4] Langer R. Tissue Engineering. Mol Ther., 2000, 1(1): 12-15.

[5] Lysaght M, Nguy N, Sullivan K, . An Economic Survey of the Emerging Tissue Engineering Industry. Tissue Eng., 1998, 4(3): 231-238.

[6] Boyan B, Lohmann C, Romero J, . Bone and Cartilage Tissue Engineering. Clin. Plast Surg., 1999, 26(4): 629-645.

[7] Baum B, Mooney D. The Impact of Tissue Engineering on Dentistry. J. Am. Dent. Assoc., 2000, 131(3): 309-318.

[8] Jankowski R, Wagner W. Directions in Cardiovascular Tissue Engineering. Clin. Plast. Surg., 1999, 26(4): 605-616.

[9] DiEdwardo C, Petrosko P, Acarturk T, . Muscle Tissue Engineering. Clin. Plast. Surg., 1999, 26(4): 647-656.

[10] Walgenbach K, Voigt M, Riabikhin A, . Tissue Engineering in Plastic Reconstructive Surgery. Anat. Rec., 2001, 263(4): 372-378.

[11] Langer R, . Tissue Engineering: Status and Challenges. E—Biomed., 2001, 1: 5-6.

[12] Vacanti J, Langer R. Tissue Engineering: the Design and Fabrication of Living Replacement Devices for Surgical Reconstruction and Transplantation. Lancet., 1999, 354(Suppl 1): SI32-34.

[13] Caplan A. Tissue Engineering Designs for the Future: New Logics, Old Molecules. Tissue Eng., 2000, 6(1): 1-8.

[14] Mitka M. Tissue Engineering Approaches Utility. JAMA, 2000, 284(20): 2582-2583.

[15] Omstead D, Baird L, Christenson L, . Volumtary Guidance for the Development of Tissue-engineered Products. Tissue Engl., 1998, 4(3): 239-266.

[16] Kim B, . Development of Biocompatible Synthetic Extracellular Matrices for Tissue Engineering. Trends Biotechnol., 1998, 16(5): 224-230.

[17] Shakesheff K, Cannizzaro S, Langer R. Creating Biomimetic Micro-environments with Synthetic Polymer-peptide Hybrid Molecules. J. Biomater. Sci. Polym. Ed., 1998, 9: 507-518.

[18] Alberts B, Bray D, Lewis J, . Molecular Biology of the Cell., 1994 3rd Ed. Wuhan: Garland Publishing Inc..

[19] Watson J, Hopkins N, Roberts J, . Molecular Biology of the Gene, 1987 4th Ed. Menlo Park: Benjamin/Cummings Publishing Inc..

[20] Vacanti J. Beyond Transplantation. Arch. Surg., 1988, 123: 545-549.

[21] Cima L, Vacanti J, Vacanti C, . Tissue Engineering by Cell Transplantation Using Degradable Polymer Substrates. J. Biomech. Eng., 1991, 113: 143-151.

[22] Thomson J, Itskovitz-Eldor J, Shapiro S, . Embryonic Stem Cell Lines Derived from Human Blastocysts. Science, 1998, 282: 1145-1147.

[23] Pittenger M, Mackay A, Beck S, . Multilineage Potential of Adult Human Mesenchymal Stem Cells. Science, 1999, 284: 143-147.

[24] Bianco M, Robey P. Stem Cells in Tissue Engineering. Nature, 2001, 414(6859): 118-121.

[25] Colman A, Kind A. Therapeutic Cloning: Concepts and Practicalities. Trends Biotechnol., 2000, 18(5): 192-196.

[26] Reddi A. Morphogenesis and Tissue Engineering of Bone and Cartilage: Inductive Signals, Stem Cells, and Biomimetic Biomaterials. Tissue Eng., 2000, 6(4): 351-359.

[27] Bissell MJ, Barcellos-Hoff MH. The Influence of Extracellular Matrix on Gene Expression: Is Structure the Message?. J. Cell Sci. (Suppl.), 1987, 8: 327-327.

[28] Athanasiou K, Zhu C, Lanctot D, . Fundamentals of Biomechanics in Tissue Engineering of Bone. Tissue Eng., 2000, 6(4): 361-381.

[29] Stading M, Langer R. Mechanical Shear Properties of Cell-polymer Cartilage Constructs. Tissue Eng., 1999, 5(3): 241-250.

[30] Ogle B, Mooradian D. The Role of Vascular Smooth Muscle Cell Integrins in the Compaction and Mechanical Strengthening of a Tissue-engineered Blood Vessel. Tissue Eng., 1999, 5: 387-402.

[31] Romano G, Michell P, Pacilio C, . Latest Developments in Gene Transfer Technology: Achievements, Perspectives, and Controversies over Therapeutic Applications. Stem Cells, 2000, 18(1): 19-39.

[32] Anderson W, Therapy Gene. The Best of Times, the Worst of Times. Science, 2000, 288(5466): 627-629.

[33] Langer R. Selected Advances in Drug Delivery and Tissue Engineering. J. Control Release, 1999, 62(1–2): 7-11.

[34] Salyapongse A, Billiar T, Edington H, . Gene Therapy and Tissue Engineering. Clin. Plast Surg., 1999, 26(4): 663-676.

[35] Gojo S, Cooper D, Iacomini J, . Gene Therapy and Transplantation. Transplantation, 2000, 69(10): 1995-1999.

[36] Whitaker M, Quirk R, Howdle S, . Growth Factor Release from Tissue Engineering Scaffolds. J. Pharm. Pharmacol., 2001, 53(11): 1427-37.

[37] Richardson T, Murphy W, Mooney D. Polymeric Delivery of Proteins and Plasmid DNA for Tissue Engineering and Gene Therapy. Crit. Rev. Eukaryot Gene Expr., 2001, 11(1–3): 47-58.

[38] Bader D, Lee D. Gene Therapy and Tissue Engineering in Orthopaedic and Sports Medicine, 2000, Boston: Birkhauser.

[39] Engel B, Kohn D. Stem Cell Directed Gene Therapy. Front Biosci., 1994, 4: 26-33.

[40] Breitbart AS, Grande DA, Mason JM, . Gene-enhanced Tissue Engineering: Applications for Bone Healing Using Cultured Periosteal Cells Transduced Retrovirally with the BMP-7 Gene. Ann. Plast. Surg., 1999, 42: 488-495.

[41] Bonadio J. Tissue Engineering Via Local Gene Delivery: Update and Future Prospects for Enhancing the Technology. Adv. Drug Deliv. Rev., 2000, 44(2–3): 185-94.

[42] Menetrey J, Kasemkijwattana C, Day C, . Direct-, Fibroblast-and Myoblast-mediated Gene Transfer to the Anterior Cruciate Ligament. Tissue Eng., 1999, 5(5): 435-442.

[43] Kim T, Lee A, Ma P. Enhanced Survival of Transgenic Hepatocytes Expressing Hepatocyte Growth Factor in Hepatocyte Tissue Engineering. Transplant Proc., 1997, 29: 858-860.

[44] Lull R. Immune Considerations in Tissue Engineering. Clin. Plast. Surg., 1999, 26(4): 549-568.

[45] Qin L, . Gene Transfer of Transforming Growth Factor-beta 1 Prolongs Murine Cardiac Allograft Survival by Inhibiting Cellmediated Immunity. Hum. Gene Ther., 1996, 7: 1981-1981.

[46] Deng S, Ketchum R, Kucher T, . Adenoviral Transfection of Canine Islet Xenografts with Immunosuppressive Cytokine Genes Abrogates Primary Nonfunction and Prolongs Graft Survival. Transplant Proc., 1997, 29: 770-770.

[47] Desai TA, . Microfabricated Immunoisolating Biocapsules. Biotechnol. Bioeng., 1998, 57: 118-118.

[48] Santini J, Cima M, Langer R. A Controlled-release Microchip. Nature, 1999, 397: 335-338.

[49] Pappas N, Langer R. New Challenges in Biomaterials. Science, 1994, 263: 1715-1715.

[50] Stupp S, . Molecular Manipulation of Microstructures: Biomaterials, Ceramics, and Semiconductors. Science, 1997, 277: 1242-1248.

[51] Hoffman A. Molecular Bioengineering of Biomaterials in the 1990s and Beyond: a Growing Liaison of Polymers with Molecular Biology. Artif. Organ., 1992, 16(1): 43-49.

[52] Hoffman A. Combining Novel Biomolecules and Stimuli Sensitive Biomaterials into New Recognition-response Biomaterial Systems. Artif. Organs, 1998, 12: 504-505.

[53] Hutmacher D. Scaffold Design and Fabrication Technologies for Engineering Tissues-state of the Art and Future Perspectives. J. Biomater. Sci. Polym. Ed., 2001, 12(1): 107-24.

[54] Wintermantel E, Mayer J, Blum J, . Tissue Engineering Scaffolds Using Superstructures. Biomaterials, 1996, 17(2): 83-91.

[55] Langer R. Drug Delivery and Targeting. Nature, 1998, 392(6679 Suppl): 5-10.

[56] Healy K, Rezania A, Stile RA. Designing Biomaterials to Direct Biological Responses. Ann. N. Y. Acad. Sci., 1999, 875: 24-24.

[57] Mazumdar S. Prospects for the Polymer Nanoengineer. Science, 2000, 288: 630-631.

[58] Guo XD, Zheng QX, Du JY, . Biodegradation and Mechanical Properties of Hydroxyapatite/poly-DL-lactide Composites for Fracture Fixation. J. Wuhan Univer sity of Technology—Mater. Sci. Ed., 1998, 13(4): 9-15.